Condition
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 1 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
1 shownCommon interventions
AbemaciclibDRUG1AbirateroneDRUG1AfatinibDRUG1BevacizumabBIOLOGICAL1BicalutamideDRUG1Biospecimen CollectionPROCEDURE1BortezomibDRUG1CabazitaxelDRUG1CabozantinibDRUG1CapecitabineDRUG1CarboplatinDRUG1CelecoxibDRUG1CobimetinibDRUG1CopanlisibDRUG1DabrafenibDRUG1DacomitinibDRUG1DarolutamideDRUG1DasatinibDRUG1DoxorubicinDRUG1DurvalumabBIOLOGICAL1EnasidenibDRUG1EntrectinibDRUG1EnzalutamideDRUG1ErlotinibDRUG1EverolimusDRUG1
Leading sponsors
Trial status mix
TERMINATED1
Phase mix
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.